AR and prostate cancer: In turn, Pt(IV) conjugate 85 (Figure 39), composed of an AR-binding nonsteroidal cyanonilutamide unit, 7-hydroxycoumarin, and cisplatin moiety, represents the AR antagonist intended for castration-resistant prostate cancer treatment [177].